57.31

1.98% -1.1956

Biomarin Pharmaceutical Inc (BMRN)

Overview News Price History Option Chain Financials Discussions Forecast

Biomarin Pharmaceutical Inc stock is traded at $57.31, with a volume of 1.62M. It is down -1.98% in the last 24 hours and down -4.21% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Previous Close:

$58.51

Open:

$56.71

24h Volume:

1.62M

Relative Volume:

0.68

Market Cap:

$11.00B

Revenue:

$2.95B

Net Income/Loss:

$523.88M

P/E Ratio:

21.31

EPS:

2.69

Net Cash Flow:

$620.18M

1W Performance:

-5.80%

1M Performance:

-4.21%

6M Performance:

+6.32%

1Y Performance:

-17.41%

1-Day Range:

$55.88

$58.80

1-Week Range:

$55.88

$61.97

52-Week Range:

$50.76

$73.18

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name

Biomarin Pharmaceutical Inc

Sector

Healthcare (1121)

Industry

Biotechnology (621)

Phone

(415) 506-6700

Address

105 DIGITAL DRIVE, NOVATO, CA

Employee

3,221

Twitter

Next Earnings Date

2026-02-23

Latest SEC Filings

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMRN Biomarin Pharmaceutical Inc	57.20	11.25B	2.95B	523.88M	620.18M	2.69
VRTX Vertex Pharmaceuticals Inc	462.12	119.23B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	754.93	78.84B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	703.89	43.35B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	316.82	41.57B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	289.08	31.51B	5.36B	287.73M	924.18M	2.5229

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-06-25	Downgrade	Stifel	Buy → Hold
Sep-08-25	Initiated	H.C. Wainwright	Neutral
Sep-03-25	Initiated	Raymond James	Outperform
Jul-03-25	Resumed	Morgan Stanley	Overweight
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-24	Initiated	Evercore ISI	Outperform
Nov-15-23	Initiated	Wells Fargo	Overweight
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jun-14-23	Resumed	Credit Suisse	Outperform
Mar-21-23	Initiated	Bernstein	Underperform
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral
Jan-30-23	Initiated	BMO Capital Markets	Market Perform
Jan-18-23	Initiated	Canaccord Genuity	Hold
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight
Jun-13-22	Resumed	Wedbush	Neutral
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy
Sep-09-21	Upgrade	Stifel	Hold → Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-04-21	Resumed	Guggenheim	Buy
Mar-01-21	Upgrade	Evercore ISI	In-line → Outperform
Aug-20-20	Downgrade	Citigroup	Buy → Neutral
Aug-20-20	Downgrade	William Blair	Outperform → Mkt Perform
Aug-19-20	Downgrade	Evercore ISI	Outperform → In-line
Aug-19-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-19-20	Downgrade	Stifel	Buy → Hold
Jul-08-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-06-20	Reiterated	Citigroup	Buy
Jan-28-20	Initiated	BMO Capital Markets	Market Perform
Jan-27-20	Initiated	BMO Capital Markets	Market Perform
Jan-24-20	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-27-19	Upgrade	Barclays	Equal Weight → Overweight
Nov-12-19	Initiated	SunTrust	Buy
Oct-17-19	Resumed	BofA/Merrill	Buy
May-23-19	Resumed	Citigroup	Buy
Apr-09-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-14-18	Initiated	Wolfe Research	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Aug-07-18	Reiterated	Stifel	Buy
Aug-03-18	Reiterated	Stifel	Buy

View All

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

12:00 PM

BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Gap DownTime to Sell? - MarketBeat

12:00 PM

11:35 AM

BioMarin Pharmaceutical (BMRN) receives FDA approval for expanded use of PALYNZIQ in adolescents - MSN

11:35 AM

11:26 AM

BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma

11:26 AM

11:18 AM

Wolfe Research reiterates Outperform on BioMarin stock at $95 By Investing.com - Investing.com India

11:18 AM

10:49 AM

BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace

10:49 AM

09:40 AM

BioMarin stops mid-stage trials of bone disorder treatment - Reuters

09:40 AM

09:21 AM

BioMarin Halts VOXZOGO Dosing in Select Phase 2 Trials - TipRanks

09:21 AM

08:48 AM

BioMarin shares drop 4% as Voxzogo trials are discontinued (BMRN:NASDAQ) - Seeking Alpha

08:48 AM

08:30 AM

BioMarin (NASDAQ: BMRN) stops VOXZOGO trials in Turner, SHOX and ACAN - Stock Titan

08:30 AM

07:49 AM

BioMarin Pharmaceutical Stock (ISIN: US09061G1013) Gains Momentum on Voxzogo Data and $4.7B Amicus A - AD HOC NEWS

07:49 AM

Mar 15, 2026

Braidwell LP Acquires Shares of 528,000 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 15, 2026

Boone Capital Management LLC Sells 118,903 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 15, 2026

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 15, 2026

Mar 14, 2026

Is It Time To Reassess BioMarin Pharmaceutical (BMRN) After Prolonged Share Price Weakness - simplywall.st

Mar 14, 2026

Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - Sahm

Mar 14, 2026

BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN

Mar 14, 2026

Dodge & Cox Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 14, 2026

12 Best Get Rich Quick Stocks to Buy According to Hedge Funds - Insider Monkey

Mar 14, 2026

Mar 13, 2026

BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents - Insider Monkey

Mar 13, 2026

Inflation Data: What is the target price for BioMarin Pharmaceutical Inc stock2026 Trends & Technical Pattern Based Signals - baoquankhu1.vn

Mar 13, 2026

EVP Of BioMarin Pharmaceutical Sold $996K In Stock - Benzinga

Mar 13, 2026

Jefferies Maintains Buy on BioMarin Pharmaceutical Inc. (BMRN) March 2026 - Meyka

Mar 13, 2026

BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference - MarketBeat

Mar 13, 2026

BioMarin Pharmaceutical touts 13% 2025 revenue growth, Amicus deal, and 2026 pipeline catalysts at Barclays event - MarketBeat

Mar 13, 2026

BioMarin reports growth data for achondroplasia drug VOXZOGO By Investing.com - Investing.com India

Mar 13, 2026

Mar 12, 2026

BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com South Africa

Mar 12, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Charles Greg Guyer Sells 16,486 Shares - MarketBeat

Mar 12, 2026

Jefferies reiterates Buy on BioMarin stock after DMD trial data - Investing.com UK

Mar 12, 2026

Jefferies reiterates Buy on BioMarin stock after DMD trial data By Investing.com - Investing.com Canada

Mar 12, 2026

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical - PR Newswire

Mar 12, 2026

First Trust Advisors LP Raises Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Capital Research Global Investors Purchases 2,145,717 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Dimensional Fund Advisors LP Purchases 671,566 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Mar 12, 2026

Mar 11, 2026

BofA cuts BioMarin stock price target to $85 on Voxzogo outlook - Investing.com UK

Mar 11, 2026

BMRN: Strong 2025 growth, major 2026 clinical milestones, and Amicus acquisition drive future outlook - TradingView

Mar 11, 2026

BMRN: Strong 2025 growth, Amicus acquisition, and key 2026 clinical milestones drive optimism - TradingView

Mar 11, 2026

Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Mar 11, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $85.00 Price Target at Bank of America - MarketBeat

Mar 11, 2026

Mar 10, 2026

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin (BMRN) - simplywall.st

Mar 10, 2026

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz - Benzinga

Mar 10, 2026